Fluoroquinolones are a class of antibiotics frequently and globally prescribed as a measure to cure bacterial infections in humans and animals. There is an extensive list of drugs in this class, but the most familiar are name brands Cipro, Levaquin (now off market), Avelox, and their generics  ciprofloxacin, levofloxacin, and moxifloxacin. 

Both U.S. and European regulators have only strengthened fluoroquinolone safety warnings over the last decade. The Food & Drug Administration (FDA) black boxed warnings state that systemic fluoroquinolones have been associated with disabling and potentially irreversible serious adverse reactions that can occur together, including tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and the worsening of myasthenia gravis. FDA warnings and labeling also address psychiatric and neurologic effects, serious blood sugar disturbances including hypoglycemia, increased risk of aortic aneurysm or dissection in certain patients, and ciprofloxacin’s inhibition of CYP1A2.  The European Medicines Agency (EMA) has issued even broader language, warning that fluoroquinolones can be associated with prolonged, disabling, and potentially irreversible serious adverse reactions affecting several, sometimes multiple, systems, organ classes, and senses. EMA examples include musculoskeletal, nervous system, psychiatric, and sensory effects, such as tendon problems, joint or limb pain, gait disturbance, neuropathy, depression, fatigue, memory impairment, sleep disorders, and impaired hearing, vision, taste, or smell.  

Most people are unaware that fluoroquinolones are used in surgical procedures via IV, Lasik, cataract surgery, and given for prophylactic measures. In addition, fluoroquinolone residues have been documented in environmental and agricultural settings, including wastewater, surface waters, sediments, soils, manure-amended fields, livestock and poultry production environments, and some animal-derived foods.  Governments, the global population, and medical communities remain largely uninformed of the growing worldwide silent epidemic of people experiencing severe adverse drug reactions in conjunction with extensive, simultaneous medical issues which receive inaccurate or no proper diagnosis.

In recent years, scientific evidence has grown that fluoroquinolones may interfere with mitochondria, the energy-producing structures inside human cells. While direct published research in affected human patients is still urgently needed, laboratory findings show that ciprofloxacin and levofloxacin can disrupt mitochondrial function in more than one way. Ciprofloxacin may interfere with how mitochondria copy and maintain their own DNA, while ciprofloxacin and levofloxacin may also affect mitochondrial proteins involved in energy production and stress responses.  Because mitochondria help power nerves, muscles, the brain, and nearly every system in the body, these findings help support a biologically plausible explanation for mitochondrial stress, impaired cell function, and disrupted energy production after fluoroquinolone exposure. Since mitochondrial dysfunction is increasingly linked to many chronic and degenerative diseases, these changes may represent an early biological warning sign, or prelude, to more serious disease processes over time. 

In 2023, over 14 million fluoroquinolone prescriptions were dispensed in the U.S., despite FDA warnings about disabling and potentially permanent side effects.  Studies estimate that 3% to 5% of users may suffer serious long-term harm, especially with repeated use, IV dosing, or underlying genetic vulnerabilities that may impair drug detoxification or cellular repair.  Less than 1% of adverse reactions are officially reported, meaning hundreds of thousands to possibly over a million Americans each year could be living with fluoroquinolone toxicity, most without recognition or support.  Tragically, millions more can be affected worldwide.